İhsan KAYA, Hasan CECE, Sema YILDIZ, Tülay DOĞANTÜRK, Sibel SEZER, Zeynep AKTI, Süleyman H. KONAR, Kadir YETİŞGİN

Assessment of physicians' awareness levels on nephrogenic systemic fibrosis

Amaç. Nefrojenik Sistemik Fibrosis (NSF), böbrek yetmezliği olan hastalarda kontrastlı manyetikrezonans görüntüleme sonrasında tanımlanan sistemik bir hastalıktır. Bu çalışma ile klinisyenlerinNSF hakkındaki bilgi düzeylerinin değerlendirilmesi amaçlanmıştır. Yöntem. Üniversite, devletve özel hastanelerde çalışan 124 klinisyen üzerinde kesitsel bir anket çalışması olarak planlandı.NSFnin böbrek yetmezliği ile olan ilişkisi, böbrek yetmezliği hastalarında NSFnin öncedentahmin edilip önlenmesine yönelik bilgi düzeyi sorgulandı. Bulgular. NSF hakkındaki yenilikleritakip etme ve hemodiyaliz yaparak NSFyi önlemeye çalışma konusunda gruplar arasında anlamlıfarklılık vardı ve farkındalık açısından üniversiteden katılan klinisyenler en iyi, devlethastanesinden katılanlar ise en kötü olduğu tespit edildi (p

Klinisyenlerin nef roj enik sistemik f ibrozis hakkındaki f arkındalık düzeyinin araştırılması

Aim. Nephrogenic systemic fibrosis (NSF) has recently defined as a systemic disorder that isidentified after performing contrast-enhanced magnetic resonance imaging in patients with renalfailure. We aimed to assess the levels of awareness of physicians on the NSF with a questionnaire.Methods. It is a cross-sectional survey study among 124 physicians working in university, state,and private hospitals. Information on awareness of physicians on the association of NSF and renaldysfunction and the presumption and prevention of NSF in the presence of renal dysfunction wereobtained using a self-administered structured questionnaire. Results. The awareness of physiciansworking in university, state and private hospitals on the novelties and prevention of NSF withperforming hemodialysis, were significantly different with best and worst awareness in physiciansfrom university and state hospitals, respectively (p

PDF

___

1. Grobner T. Gadolinium: a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006; 21: 1104-8.
2. Marckmann P, Skov L, Rossen K, Dupont A, Damholt MB, Heaf JG, Thomsen HS. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 2006; 17: 2359-62.
3. Agarwal R, Brunelli SM, Williams K, Mitchell MD, Feldman HI, Umscheid CA. Gadolinium based contrast agents and nephrogenic systemic fibrosis: a systematic review and meta-analysis. Nephrol Dial Transplant 2009; 24: 856-63.
4. Thomsen HS. Guidelines on contrast media. In: Thomsen HS, Webb JAW, eds. Contrast media: safety issues and ESUR guidelines. 2nd revised ed. Heidelberg: Springer Verlag 2009: 229-42.
5. American College of Radiology. Manual on Contrast Media. 7th ed. Reston, Virgina: ACR; 2010: 49-55.
6. Marckmann P, Skov L. Nephrogenic systemic fibrosis: clinical picture and treatment. Radiol Clin North Am 2009; 47: 833-40.
7. Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, LeBoit PE. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 2000; 356: 1000-1.
8. Streams BN, Liu V, Liégeois N, Moschella SM. Clinical and pathologic features of nephrogenic fibrosing dermopathy: a report of two cases. J Am Acad Dermatol 2003; 48: 42-7.
9. Cowper SE, Su LD, Bhawan J, Robin HS, LeBoit PE. Nephrogenic fibrosing dermopathy. Am J Dermatopathol 2001; 23: 383-93.
10. Gibson SE, Farver CF, Prayson RA. Multiorgan involvement in nephrogenic fibrosing dermopathy: an autopsy case and review of the literature. Arch Pathol Lab Med 2006; 130: 209-12.
11. Keyrouz S, Rudnicki SA. Neuromuscular involvement in nephrogenic systemic fibrosis. J Clin Neuromuscul Dis 2007; 9: 297-302.
12. Ting WW, Stone MS, Madison KC, Kurtz K. Nephrogenic fibrosing dermopathy with systemic involvement. Arch Dermatol 2003; 139: 903-6.
13. Broome DR, Girguis MS, Baron PW, Cottrell AC, Kjellin I, Kirk GA. Gadodiamide-associated nephrogenic systemic fibrosis: Why radiologists should be concerned. Am J Roentgenol 2007; 188: 586-92.
14. Knopp EA, Cowper SE. Nephrogenic systemic fibrosis: early recognition and treatment. Semin Dial 2008; 21: 123-8.
15. Thomsen HS, Marckmann P. Extracellular gd-CA: differences in prevalence of NSF. Eur J Radiol 2008; 66: 180-3.
16. Othersen JB, Maize JC, Woolson RF, Budisavljevic MN. Nephrogenic systemic fibrosis after exposure to gadolinium in patients with renal failure. Nephrol Dial Transplant 2007; 22: 3179-85.
17. Cowper SE. Nephrogenic systemic fibrosis: A Review and Exploration of the Role of Gadolinium. Adv Dermatol 2007; 23: 131-54.
18. Broome DR. Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: a summary of the medical literature reporting. Eur J Radiol 2008; 66: 230-4.
19. Marckmann P. Nephrogenic systemic fibrosis: epidemiology update. Curr Opin Nephrol Hypertens 2008; 17: 315-9.
20. Todd DJ, Kay J. Nephrogenic systemic fibrosis: an epidemic of gadolinium toxicity. Curr Rheumatol Rep 2008; 10: 195-204.
21. Cowper SE, Rabach M, Girardi M. Clinical and histological findings in nephrogenic systemic fibrosis. Eur J Radiol 2008; 66: 191-9 .
22. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Part 5. Evaluation of Laboratory Measurements for Clinical Assessment of Kidney Disease. Guideline 4. Estimation of GFR. Am J Kidney Dis 2002; 39: 76S-110S.
23. Abdel-Kader K, Patel PR, Kallen AJ, Sinkowitz-Cochran RL, Bolton WK, Unruh ML. Nephrogenic Systemic Fibrosis: A Survey of Nephrologists' Perceptions and Practices. Clin J Am Soc Nephrol 2010; 5: 964-71.